Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 6725073, 6 pages
http://dx.doi.org/10.1155/2016/6725073
Research Article

Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA

1Department of Infectious Disease, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
2Department of Infectious Disease, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China

Received 30 November 2015; Revised 22 January 2016; Accepted 7 February 2016

Academic Editor: Fumio Imazeki

Copyright © 2016 Hong Shi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Safioleas, N. J. Lygidakis, and C. Monti, “Hepatitis B today,” Hepato-Gastroenterology, vol. 54, no. 74, pp. 545–548, 2007. View at Google Scholar · View at Scopus
  2. F.-S. Wang, J.-G. Fan, Z. Zhang, B. Gao, and H.-Y. Wang, “The global burden of liver disease: the major impact of China,” Hepatology, vol. 60, no. 6, pp. 2099–2108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. E. B. Keeffe, D. T. Dieterich, S.-H. B. Han et al., “A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update,” Clinical Gastroenterology and Hepatology, vol. 6, no. 12, pp. 1315–1341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. J. Hadziyannis, N. C. Tassopoulos, E. J. Heathcote et al., “Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years,” Gastroenterology, vol. 131, no. 6, pp. 1743–1751, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. Y.-F. Liaw, E. Gane, N. Leung et al., “2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B,” Gastroenterology, vol. 136, no. 2, pp. 486–495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B: update 2009,” Hepatology, vol. 50, no. 3, pp. 661–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. Y.-F. Liaw, J.-H. Kao, T. Piratvisuth et al., “Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update,” Hepatology International, vol. 6, no. 3, pp. 531–561, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. European Association for the Study of the Liver, “EASL clinical practice guidelines: management of chronic hepatitis B virus infection,” Journal of Hepatology, vol. 57, no. 1, pp. 167–185, 2012. View at Publisher · View at Google Scholar
  9. M. Huang, Y. Jie, H. Shi et al., “Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in China,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 1, pp. 666–673, 2015. View at Google Scholar · View at Scopus
  10. S.-K. Kim, D.-J. Kim, S.-H. Kim et al., “Normal range of alanine aminotransferase concentration is associated with carotid atherosclerosis,” Diabetes Research and Clinical Practice, vol. 88, no. 1, pp. 111–116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C.-J. Chen, H.-I. Yang, J. Su et al., “Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level,” The Journal of the American Medical Association, vol. 295, no. 1, pp. 65–73, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. U. H. Iloeje, H.-I. Yang, J. Su, C.-L. Jen, S.-L. You, and C.-J. Chen, “Predicting cirrhosis risk based on the level of circulating hepatitis B viral load,” Gastroenterology, vol. 130, no. 3, pp. 678–686, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. U. H. Iloeje, H.-I. Yang, and C.-J. Chen, “Natural history of chronic hepatitis B: what exactly has REVEAL Revealed?” Liver International, vol. 32, no. 9, pp. 1333–1341, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Gauthier, E. J. Bourne, M. W. Lutz et al., “Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine,” The Journal of Infectious Diseases, vol. 180, no. 6, pp. 1757–1762, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. C.-H. Chen, J.-H. Wang, S.-N. Lu et al., “Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience,” Liver International, vol. 31, no. 2, pp. 206–214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. T.-T. Chang, R. G. Gish, R. De Man et al., “A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B,” The New England Journal of Medicine, vol. 354, no. 10, pp. 1001–1010, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Marcellin, E. J. Heathcote, M. Buti et al., “Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B,” The New England Journal of Medicine, vol. 359, no. 23, pp. 2442–2455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Batirel, E. Guclu, F. Arslan et al., “Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study,” International Journal of Infectious Diseases, vol. 28, pp. e153–e159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Ceylan, C. Yardimci, M. Fincanci et al., “Comparison of tenofovir and entecavir in patients with chronic HBV infection,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 18, pp. 2467–2473, 2013. View at Google Scholar · View at Scopus
  20. L. Gao, H. N. Trinh, J. Li, and M. H. Nguyen, “Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA,” Alimentary Pharmacology & Therapeutics, vol. 39, no. 6, pp. 629–637, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Lampertico, M. Vigano, R. Soffredini et al., “Entecavir monotherapy in 418 nuc-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment,” in Hepatology, p. 1043A, Wiley-Blackwell Commerce Place, Malden, Mass, USA, 2011. View at Google Scholar
  22. E. Ridruejo, R. Adrover, D. Cocozzella et al., “Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice,” International Journal of Clinical Practice, vol. 65, no. 8, pp. 866–870, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Lampertico, R. Soffredini, M. Viganò et al., “2-Year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practive,” Hepatology, vol. 54, supplement 1, abstract 1433, 2011. View at Google Scholar
  24. W. Ke, L. Liu, C. Zhang et al., “Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis,” PLoS ONE, vol. 9, no. 6, Article ID e98865, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. S. R. Zuo, X. C. Zuo, C. J. Wang et al., “A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection,” The Journal of Clinical Pharmacology, vol. 55, no. 3, pp. 288–297, 2015. View at Publisher · View at Google Scholar
  26. C.-J. Liu, P.-J. Chen, M.-Y. Lai et al., “Viral factors correlate with hepatitis B e antigen seroconverson in patients with chronic hepatitis B,” Liver International, vol. 26, no. 8, pp. 949–955, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Dakin, C. Fidler, and C. Harper, “Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B,” Value in Health, vol. 13, no. 8, pp. 934–945, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. J. Heathcote, P. Marcellin, M. Buti et al., “Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B,” Gastroenterology, vol. 140, no. 1, pp. 132–143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Leung, C. Peng, J. Sollano et al., “Entecavir (ETV) results in higher HBV DNA reduction versus adefovir (ADV) in antiviral-naïve HBeAg(+) adults with high HBV DNA: week 96 results (EARLY Study),” Journal of Hepatology, vol. 48, pp. S373–S374, 2008. View at Google Scholar
  30. M. R. Nelson, C. Katlama, J. S. Montaner et al., “The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years,” AIDS, vol. 21, no. 10, pp. 1273–1281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. G. L. Wong, Y. K. Tse, V. W. Wong, T. C. Yip, K. K. Tsoi, and H. L. Chan, “Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects,” Hepatology, vol. 62, no. 3, pp. 684–693, 2015. View at Publisher · View at Google Scholar
  32. N. B. Ha, K. Ku, N. B. Ha, K. T. Chaung, H. N. Trinh, and M. H. Nguyen, “Renal function in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or entecavir monotherapy: a matched case-cohort study,” Journal of Clinical Gastroenterology, vol. 49, no. 10, pp. 873–877, 2015. View at Publisher · View at Google Scholar